Following a successful, oversubscribed late seed funding, the company now works from labs at the Babraham Research Campus. The company’s proprietary technology, PolyNaut® can be applied to both clinical and non clinical/ex vivo products.
ViaNautis works with pharma and biotech partners for innovation and problem solving in neurology, oncology and immune diseases. Our partners Abcam PLC market and develop non-clinical products.
A female-led preclinical biotech start-up, Vitarka Therapeutics is focused on revolutionising the market for non-viral drug delivery technology. The company is developing combination medicines using RNAi therapies and a non-viral drug delivery platform. Their novel tumour-targeted platform technology, EndoPore, targets solid tumours and delivers therapeutics for intracellular targets.
